Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Buy” by Analysts
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given a consensus recommendation of “Buy” by the twenty-four brokerages that are presently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $60.73.
Several analysts have issued reports on the company. Piper Jaffray Companies set a $43.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 18th. Vetr lowered Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $36.86 target price for the company. in a research note on Monday, May 15th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, June 22nd. BidaskClub lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $69.00 target price (up previously from $62.00) on shares of Sarepta Therapeutics in a research note on Thursday, July 20th.
TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Buy” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/11/sarepta-therapeutics-inc-nasdaqsrpt-given-average-recommendation-of-buy-by-analysts.html.
Sarepta Therapeutics (SRPT) traded up 0.89% on Friday, hitting $37.35. 773,926 shares of the stock were exchanged. The firm’s market cap is $2.40 billion. The company has a 50-day moving average price of $36.95 and a 200-day moving average price of $32.78. Sarepta Therapeutics has a 52-week low of $24.31 and a 52-week high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. The firm’s quarterly revenue was up 350000.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.19) EPS. On average, equities research analysts anticipate that Sarepta Therapeutics will post ($1.16) EPS for the current fiscal year.
In related news, SVP Alexander Cumbo sold 5,918 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at $934,513. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Douglas S. Ingram purchased 47,058 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the completion of the purchase, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of SRPT. Renaissance Technologies LLC purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at $1,346,000. Norges Bank purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at $11,181,000. Teachers Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 190.1% in the fourth quarter. Teachers Advisors LLC now owns 222,786 shares of the biotechnology company’s stock valued at $6,111,000 after buying an additional 146,002 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at $905,000. Finally, Bank of Montreal Can boosted its stake in shares of Sarepta Therapeutics by 1.0% in the first quarter. Bank of Montreal Can now owns 98,775 shares of the biotechnology company’s stock valued at $2,924,000 after buying an additional 996 shares during the last quarter. 64.58% of the stock is currently owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.